Extended interval dosing of natalizumab: a two-center, 7-year experience

Conclusion: Natalizumab is effective in controlling MS as very few clinical relapses were observed in our dataset. We found that EID did not compromise the treatment effect as measured by relapse rate and no significant breakthrough disease activity was observed. EID is an optional regimen for maintenance natalizumab therapy, but prospective studies are warranted to determine its efficacy.
Source: Therapeutic Advances in Neurological Disorders - Category: Neurology Authors: Tags: Original Research Source Type: research